Publications

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer

Alagesan B, Varghese AM, Ang C, Gutierrez M, Kamar M, Passhak M, Geva R, Yarom N, et al.

Clin Cancer Res

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848

Abrams RA, Winter KA, Goodman KA, Regine WF, Safran HP, Guha CS, Kachnic LA, Gillin MT, et al.

J Clin Oncol

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lavoie Smith EM, Lee M, Scott MR, Liu H, Hillman S, Rieken T, Wills R, Diaz-Cobo J, et al.

JCO Oncol Adv

Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study

Manji GA, Chung V, Oh DY, Lacy J, Lopez CD, Ponz-Sarvisé M, Macarulla T, Thomas R, et al.

Oncologist

Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials

Lewis KA, Colgrove BA, Nelson GD, Shi Q, Edwards GC, Katz MHG, Chang GJ, Paskett ED, et al.

JCO Oncol Pract

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors

Melero I, Tabernero J, Steeghs N, Robbrecht DGJ, Peters S, Rizvi NA, O'Reilly EM, Calvo E, et al.

Clin Cancer Res

Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer

Hong J, Kohutek ZA, Zhang H, Lecomte N, Karnoub ER, Kappagantula R, Wood LD, O'Reilly EM, et al.

Cancer Discov

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Harvey RN, Gelfer R, Drill E, Balachandran V, D'Angelica M, Drebin J, Kingham TP, Saadat L, et al.

JCO Precis Oncol

Genomic evolution of pancreatic cancer at single-cell resolution

Zhang H, Sashittal P, Karnoub ER, Jakatdar A, Umeda S, Hong J, Noronha AM, Cardenas A 3rd, et al.

Nat Genet

Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma

Misyura M, Selenica P, Ozcan K, Kemel Y, Basturk O, O'Reilly EM, Reis-Filho JS, Beets-Tan R, et al.

JCO Precis Oncol

IL10R Inhibition Induces Neutrophil Tumoricidal Activity

Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, et al.

Cancer Immunol Res

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, et al.

Future Oncol

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, et al.

Clin Cancer Res

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer

Schram AM, Yang SR, Kahn G, Velasco R, Repetto M, Kinh Gian Do R, DiNapoli S, Sukhadia P, et al.

J Natl Cancer Inst

Pancreatic cancer

Roth S, Apte M, Balachandran VP, Biffi G, Conroy T, Cukierman E, Dotan E, Esposito I, et al.

Nat Rev Dis Primers

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms

O'Reilly EM

Nat Rev Gastroenterol Hepatol

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Cancer Discov

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Nature Medicine

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

bioRxiv

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, et al.

Nat Med

Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation

Cardell CF, Segovia D, Prakash LR, Zemla T, Shi Q, Ahmad S, Herman JM, O'Reilly EM, et al.

JCO Oncol Pract

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer

Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, et al.

Cancer Res

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

May MS, Park W, O'Reilly EM

Drugs

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

Paudyal R, Russell J, Lekaye HC, Deasy JO, Humm JL, Awais M, Nadeem S, Do RKG, et al.

Cancers (Basel)

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

J Natl Cancer Inst

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Tsang ES, Shi Q, Olive K, Collisson E, Dixon JG, Cusnir M, Winograd R, Botta GP, et al.

JCO Oncol Adv

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, et al.

JCO Precis Oncol

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

J Natl Cancer Inst

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Nature Medicine 31(2), 466–477

Early-Phase Trials in Journal of Clinical Oncology

Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG

J Clin Oncol

Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer

Schleimer LE, Aviki E, Kalvin HL, Magnin J, Sokolowski SS, Kingham TP, O'Reilly EM, Varghese AM, et al.

JCO Oncol Pract

Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma

Judge SJ, Manin E, Chou J, Torphy RJ, McIntyre CA, Balachandran VP, D'Angelica MI, Drebin JA, et al.

Cancer

International Fibrolamellar Cancer Registry: Opportunities and Challenges

Al Mahmasani L, Capanu M, Losert K, Chou JF, Lowery MA, Hennessy M, Ray M, Chambers S, et al.

JCO Glob Oncol

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, Connell L, Harding J, et al.

JCO Precis Oncol

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, et al.

Nat Med

Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer

Chuong MD, O'Reilly EM, Herrera RA, Zinovoy M, Mittauer KE, Rubens M, Kaiser A, Romesser PB, et al.

Cancers (Basel)

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Knox JJ, O'Kane G, King D, Laheru D, Habowski AN, Yu K, Perez K, Aguirre AJ, et al.

J Clin Oncol

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Res Sq

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, et al.

J Clin Oncol

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Nature 639(8056), 1042–1051

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)

Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, Shergill AP, Ma C, et al.

J Natl Cancer Inst

The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

Hayashi A, Ho YJ, Makohon-Moore AP, Zucker A, Hong J, Umeda S, Karnoub ER, Huang J, et al.

Cancer Res Commun

Utilizing Patient Input in Rectal Cancer Trial Design

Alvarez J, Zambare W, George M, Garcia R, Gallagher P, Kitchens C, Bercz A, Kim MJ, et al.

J Natl Cancer Inst

Automated real-world data integration improves cancer outcome prediction

Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, …

Nature 636(8043), 728–736

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, et al.

Cancer Res Commun

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padrón LJ, Maurer DM, et al.

Nat Commun

Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

McIntyre SM, Preston WA, Walch H, Sharib J, Kundra R, Sigel C, Lidsky ME, Allen PJ, et al.

JCO Precis Oncol

Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome

Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, Cercek A, Abou-Alfa G, et al.

JCO Precis Oncol

Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study

Dekker EN, van Dam JL, Janssen QP, Besselink MG, DeSilva A, Doppenberg D, van Eijck CHJ, Nasar N, et al.

J Clin Oncol

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, et al.

J Clin Oncol

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers

Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, O'Reilly EM, Park W, et al.

JCO Precis Oncol

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, et al.

Nat Med

Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KE, Hanna S, et al.

Nat Med

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E

Nat Rev Clin Oncol

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.

J Natl Cancer Inst

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, et al.

J Clin Med

Targeting KRAS in cancer

Singhal A, Li BT, O'Reilly EM

Nat Med

Therapeutic developments in pancreatic cancer

Hu ZI, O'Reilly EM

Nat Rev Gastroenterol Hepatol

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, et al.

J Clin Oncol

Association between physical activity and the time course of cancer recurrence in stage III colon cancer

Brown JC, Ma C, Shi Q, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, et al.

Br J Sports Med

Biospecimen Repositories in Low- and Middle-Income Countries: Insights From an American University of Beirut and Memorial Sloan Kettering Collaboration

Faraj W, Robson M, Tawil A, Reuter V, Mahfouz R, Cambria R, Saheb N, Ferrer CS, et al.

JCO Glob Oncol

Does acute pancreatitis herald pancreatic ductal adenocarcinoma? A multicenter electronic health research network study

Singh RR, Klein AP, Sharma NR, O'Reilly EM

Cancer Med

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

Keane F, Bajwa R, Selenica P, Park W, Roehrl MH, Reis-Filho JS, Mandelker D, O'Reilly EM

NPJ Precis Oncol

Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer

O'Reilly EM

J Clin Oncol

Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma

Ecker BL, Tao AJ, Janssen QP, Walch HS, Court CM, Balachandran VP, Crane CH, D'Angelica MI, et al.

Clin Cancer Res

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Mandelker D, Marra A, Zheng-Lin B, Selenica P, Blanco-Heredia J, Zhu Y, Gazzo A, Wong D, et al.

J Clin Oncol

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane F, O'Connor CA, Park W, Seufferlein T, O'Reilly EM

Cancers (Basel)

Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes

Gu L, Mehta PP, Rao D, Rotemberg V, Capanu M, Chou J, Lin S, Sigel CS, et al.

Cancer Med

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, et al.

J Clin Oncol

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, … Park W, …

Nature 618(7963), 144–150

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

Brown JC, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, Kumar P, Tan B, et al.

Cancer

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Brown JC, Ma C, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Couture F, et al.

J Clin Oncol

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Wang QL, Ma C, Yuan C, Shi Q, Wolpin BM, Zhang Y, Fuchs CS, Meyer J, et al.

Clin Cancer Res

Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702

Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, et al.

J Clin Oncol

Preoperative Treatment of Locally Advanced Rectal Cancer

Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, et al.

N Engl J Med

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

Yu KH, Cockrum P, Surinach A, Lamarre N, Wang S, O'Reilly EM

Cancer Med

Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)

Lee S, Ma C, Shi Q, Meyers J, Kumar P, Couture F, Kuebler P, Krishnamurthi S, et al.

Br J Cancer

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Augustinus S, van Laarhoven HWM, Cirkel GA, de Groot JWB, Groot Koerkamp B, Macarulla T, Melisi D, O'Reilly EM, et al.

Cancers (Basel)

Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

Yu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, et al.

Cancer

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

Clin Cancer Res

Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention

Giraldo NA, Drill E, Satravada BA, Dika IE, Brannon AR, Dermawan J, Mohanty A, Ozcan K, et al.

Clin Cancer Res

Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options

Ozer M, Ranganathan M, Lecomte N, Schvartzman JM, Walch HS, Chatila WK, Hong J, Carlo MI, et al.

JCO Precis Oncol

Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma

McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, et al.

J Surg Oncol

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, et al.

Mol Diagn Ther

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, et al.

J Clin Oncol

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)

Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, et al.

Clin Cancer Res

Precision Medicine and Immunotherapy in GI Cancers

O'Reilly EM, Ko AH

J Clin Oncol

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, et al.

Nat Med

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, et al.

J Natl Cancer Inst

Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence

Snyder RA, O'Reilly EM

J Clin Oncol

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, et al.

Cancer Discov

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study

Harding JJ, Yang TS, Chen YY, Feng YH, Yen CJ, Ho CL, Huang WT, El Dika I, et al.

Cancer

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, et al.

Nat Commun

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, et al.

Cancer

Pancreas cancer: Therapeutic trials in metastatic disease

Smithy JW, O'Reilly EM

J Surg Oncol

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma

Askan G, Sahin IH, Chou JF, Yavas A, Capanu M, Iacobuzio-Donahue CA, Basturk O, O'Reilly EM

BMC Cancer

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, et al.

Commun Biol

Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma

Lebenthal JM, Zheng J, Glare PA, O'Reilly EM, Yang AC, Epstein AS

Cancer

Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, et al.

J Clin Oncol

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, et al.

Cancers (Basel)

Targeting DNA damage repair pathways in pancreas cancer

Crowley F, Park W, O'Reilly EM

Cancer Metastasis Rev

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, et al.

J Clin Oncol

Treatment patterns and survival in patients with early-onset pancreatic cancer

Saadat LV, Chou JF, Gonen M, Soares KC, Kingham TP, Varghese AM, Jarnagin WR, D'Angelica MI, et al.

Cancer

A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma

Hayashi A, Fan J, Chen R, Ho YJ, Makohon-Moore AP, Lecomte N, Zhong Y, Hong J, et al.

Nat Cancer

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

Cancer 126(17), 3939–3949

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

Guercio BJ, Zhang S, Venook AP, Ou FS, Niedzwiecki D, Lenz HJ, Innocenti F, Mullen BC, et al.

JNCI Cancer Spectr

Duration of therapy for locally advanced pancreatic cancer: Does it matter?

Tuli R, David J, Lobaugh S, Zhang Z, O'Reilly EM

Cancer Med

Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma

Hayashi A, Yavas A, McIntyre CA, Ho YJ, Erakky A, Wong W, Varghese AM, Melchor JP, et al.

Mod Pathol

Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings

Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, et al.

Cancer

Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver

El Dika I, Bowman AS, Berger MF, Capanu M, Chou JF, Benayed R, Zehir A, Shia J, et al.

Cancer

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Singh RR, O'Reilly EM

Drugs

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, et al.

Cancer Med

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes

O'Reilly EM, Cockrum P, Surinach A, Wu Z, Dillon A, Yu KH

Cancer Med

Reply to Nutritional support in pancreatic cancer

Moffat GT, Epstein AS, O'Reilly EM

Cancer

Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study

Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, et al.

Cancer Med

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, et al.

Cancer Med

Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes

Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, et al.

Cancer

Pancreatic cancer-A disease in need: Optimizing and integrating supportive care

Moffat GT, Epstein AS, O'Reilly EM

Cancer

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, et al.

Cancer

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM

J Immunother Cancer

Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma

Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, et al.

Cancers (Basel)

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior

Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM

BMC Cancer

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, et al.

Cancer

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, et al.

Invest New Drugs